GW Pharmaceuticals price target raised to $162 from $142 at Oppenheimer

Oppenheimer analyst Esther Rajavelu raised her price target for GW Pharmaceuticals to $162 from $142 following a brief poll to screen for prescribers’ views on Epidiolex and gauge potential for broader uptake. The analyst notes that a majority of respondents have prescribed Epidiolex to less than 5% of patients, however, they consider it equally as/more effective than other therapies. Further, most have had less than 10% of treated patients experience adverse events, an almost equal proportion of prescribers manage AEs by reducing Epidiolex or other medications, and over next 12-18 months, most respondents plan to increase Epidiolex prescriptions, she adds. Rajavelu continues to view GW Pharmaceuticals as a good launch story. She reiterates a Perform rating on the shares.

https://thefly.com/landingPageNews.php?id=2898915